Form 4: Tandem Diabetes Care Executive Rick Carpenter Reports Stock Transactions
SEC Form 4 Filing
Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reports acquisition and disposal of company stock and restricted stock units.
Summary
- Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, filed a Form 4 detailing changes in beneficial ownership.
- On May 15, 2025, Carpenter acquired 1,020 shares of common stock through the Employee Stock Purchase Plan at $15.64 per share.
- He also acquired shares through the vesting of restricted stock units (RSUs): 596, 1,437, and 3,589 shares.
- Carpenter disposed of 214, 515, and 1,285 shares to cover tax withholding requirements related to RSU vesting, at a price of $22.7 per share.
- Following these transactions, Carpenter beneficially owns 21,020 shares of Tandem Diabetes Care common stock.
- The RSUs vest in installments, with the initial 33% vesting on May 15th of each year (2023, 2024, and 2025) and the remaining shares vesting quarterly thereafter.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and reflect standard compensation practices. There is no indication of unusual activity or concern.
Positives
- The acquisition of shares through the Employee Stock Purchase Plan indicates Carpenter's investment in the company's future.
- The vesting of RSUs is a form of compensation that aligns Carpenter's interests with those of the shareholders.
Negatives
- The disposal of shares to cover tax obligations reduces Carpenter's overall holdings, although this is a common practice.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often viewed as a reflection of management's confidence in the company's prospects. Form 4 filings are a standard part of regulatory compliance.
Comparison to Industry Standards
- Executive compensation packages in the medical device industry often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules for RSUs typically range from three to five years, with quarterly or annual vesting installments after an initial cliff period.
- Tax withholding practices on RSU vesting are standard across the industry.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- They provide transparency into executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 05/25/2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan. |
| 05/15/2023 | First vesting date (33%) for RSU awarded on May 25, 2022. |
| 05/25/2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan. |
| 05/15/2024 | First vesting date (33%) for RSU awarded on May 25, 2023. |
| 05/23/2024 | Date of RSU award pursuant to the 2023 Plan. |
| 11/18/2024 | Start date of ESPP purchase period. |
| 05/15/2025 | Date of transactions reported: ESPP purchase, RSU vesting, and tax withholding; First vesting date (33%) for RSU awarded on May 23, 2024; End date of ESPP purchase period. |
| 05/19/2025 | Date of Form 4 filing. |
Keywords
Tandem Diabetes Care, Rick Carpenter, Form 4, stock, RSU, beneficial ownership, employee stock purchase plan, vesting, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.